This manuscript can be published after addressing the major comments below:

1. It is recommended to change the title to “Novel Concentric Magnetic Continuum Robot with Multiple Stiffness Modes for Potential Delivery of Nanomedicine” as no targeted delivery is involved in the work.

2. Experimental details are missing. A separate section “Materials and Methods” should be added detailing where they purchased all materials, methods used, and the experimental procedure for all their experiments, particularly nanomedicine delivery using C-MCR as it is not clear.

3. In the introduction, the authors should compare this work to their previous cited work (ref. 15) to show the advantage of C-MCR.
   https://ieeexplore.ieee.org/document/9361309

4. What is the advantage of BA mode in comparison to AB mode? Is not clear in the discussion.

5. Two or more sentences on the importance of meso-tetra(p- 266 hydroxyphenyl) porphine (m-THPP) should be added. Its photodynamic properties, photobleaching, and why it is used here for glioma cancer cells.

6. Cell viability assay is not clear, particularly the relation between Figure 8d and Figures 8a-c.

   What is Figure 8a? SEM image of gold-plated nanomedicine? How did they perform SEM (materials and methods) etc.

   What is Figure 8b? TIE image!

   Better to change the legend in Figure 8c, with irradiation and without irradiation.

   I don’t understand the role of C-MCR in delivering m-THPP into the cell culture? From the experimental procedure section 2.3.2 (line171), it seems they are just adding nanomedicine. So, where did they prove delivering m-THPP to GL-261 cells *via* C-MCR? Figure 8d is just a cartoon and doesn’t show how it is done in practice.

   Ideally the experiment should consist of m-THPP simply incubated with cancer cells, and m-THPP delivered using C-MCR. Figure 8c should include additional sets to prove the efficiency of C-MCR.

7. More anti-cancer drugs should be investigated (such as delivery of Doxorubicin or any other anticancer drug they have using C-MCR). This will show the applicability of the method.

8. This work is not comprehensive and conclusive without tumor tissue. The authors should prove their concept to deliver m-THPP or nanomedicines using C-MCR by incubating with spheroids or tumor brain biopsy. Then, only they can prove if enhanced penetration through tumor tissue will be observed by C-MCR, keeping in mind the extreme difficulty of nanomedicine penetration throughout the tumor microenvironment.

9. The authors claim that “our experiments show that the C-MCR not only possesses exceptional dexterity but also successfully solves the problem of targeted long-range delivery of nanomedicines”(line 305) is not proven experimentally in this work. It is rather theoretical.

10. The below references should be cited:

    https://onlinelibrary.wiley.com/doi/full/10.1002/aisy.202200416
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227420/